Toxicity associated with epirubicin treatments in a large case series of dogs

Marrington, A. M.; Killick, David; Grant, Iain; Blackwood, Laura

doi:10.1111/j.1476-5829.2011.00281.x

Cited by 15 publications

(19 citation statements)

References 26 publications

(38 reference statements)

Supporting

Mentioning

Contrasting

Order By: Relevance

“…, Marrington et al . , Rivera et al . ) but these studies all rely on subjective owner reports, in some cases months after the treatment took place (Mellanby et al .…”

Section: Discussionmentioning

confidence: 99%

See 1 more Smart Citation

Use of accelerometry to investigate physical activity in dogs receiving chemotherapy

Helm

McBrearty

Fontaine

et al. 2016

J of Small Animal Practice

View full text Add to dashboard Cite

1Corresponding author email: jenny.helm@glasgow.ac.uk O BJECTIVES : To perform a preliminary study to assess whether single-agent palliative or adjuvant chemotherapy has an impact on objectively measured physical activity in dogs.M ETHODS : Fifteen dogs with neoplasia (treatment group) wore ActiGraph™ accelerometers for 5-day periods before, during and after receiving single-agent adjuvant or palliative chemotherapy. Mean 5-day total physical activity and time spent in three different intensities of activity (sedentary, light-moderate and vigorous) before, during and after receiving chemotherapy were compared to a group of 15 healthy dogs (control group). Results were also compared within the treatment group across time.R ESULTS : Prior to chemotherapy, treated dogs tended to be less active than control dogs. Treatment group dogs were slightly more active at restaging than they were prior to treatment but had similar activity levels to control dogs. Marked effects of chemotherapy on physical activity were not detected.Physical activity was slightly lower in treated dogs during chemotherapy when compared to control dogs but there was a slight increase in physical activity of treated dogs during chemotherapy when compared with pretreatment recordings. There was little change in the mean 5-day total physical activity between treated dogs during chemotherapy and at restaging but a mild decrease in time spent sedentary and increase in time spent in light-moderate activity at this comparison of time points. C LINICAL S IGNIFICANCE : Single-agent adjuvant or palliative chemotherapy had minimal impact on physical activity levels in dogs with neoplasia.

show abstract

“…, Marrington et al . , Rivera et al . ) but these studies all rely on subjective owner reports, in some cases months after the treatment took place (Mellanby et al .…”

Section: Discussionmentioning

confidence: 99%

“…, Marrington et al . ). It remains unknown to what extent reductions in PA actually occur in patients receiving these chemotherapeutic agents and objective measurements of PA in veterinary patients receiving chemotherapy has not been attempted.…”

Section: Introductionmentioning

confidence: 97%

Use of accelerometry to investigate physical activity in dogs receiving chemotherapy

Helm

McBrearty

Fontaine

et al. 2016

J of Small Animal Practice

View full text Add to dashboard Cite

show abstract

“…Alternating lomustine with an anthracycline increases the dosing interval for the former, allowing more time for mild hepatopathies to improve, and potentially reducing the need for a high cumulative lomustine dose. The dose‐limiting toxicity of epirubicin is usually GI toxicity, as with doxorubicin …”

Section: Discussionmentioning

confidence: 99%

“…Epirubicin has been evaluated as part of a combination chemotherapy protocol for the treatment of canine lymphoma and also in the adjunctive treatment of canine HSA and outcomes are comparable with those reported for doxorubicin …”

Section: Introductionmentioning

confidence: 92%

Epirubicin in the treatment of canine histiocytic sarcoma: sequential, alternating and rescue chemotherapy

Mason

Finotello

Blackwood

2017

Vet Comparative Oncology

Self Cite

View full text Add to dashboard Cite

The aims of this study were to report treatment outcomes for dogs with histiocytic sarcoma (HS) treated with both lomustine and epirubicin, and to report response rates to epirubicin as a rescue therapy in dogs previously treated with lomustine. Medical records of dogs with a diagnosis of HS that were treated with both lomustine and epirubicin were retrospectively evaluated. Of 29 dogs receiving epirubicin alternating with, or subsequent to lomustine treatment, including in a rescue setting, response to epirubicin could be assessed in 20 with an overall response rate (ORR) of 29% and biological response rate (BRR) of 71%. Median time to progression (TTP) in 12 of these 20 dogs in which it was assessable was 69 days (range: 40-125 days). For dogs treated in the rescue setting epirubicin specific ORR was 19% and BRR 63%. Median TTP in the 9 of these 16 dogs in which it was assessable was 62 days (range: 40-125 days). Median survival time for all dogs treated with both epirubicin and lomustine was 185 days (range: 27-500 days). Some dogs with HS respond to epirubicin and dogs treated with combinations of epirubicin and lomustine have modestly improved survival times compared with single agent studies, and similar to dogs with HS treated with alternating lomustine and doxorubicin. Single agent epirubicin is also a valid short term rescue therapy for canine HS.

show abstract

“…While hypersensitivity to doxorubicin/epirubicin infusion has been reported in dogs (Ogilvie et al 1989, Marrington et al 2012, Elliott et al 2013, these reactions appear to be rare. There are no reports of hypersensitivity to epirubicin in cats.…”

Section: Hypersensitivity Reaction During Epirubicin Infusion In a Catmentioning

confidence: 99%

Hypersensitivity reaction during epirubicin infusion in a cat

Elliott

2015

J of Small Animal Practice

View full text Add to dashboard Cite

LETTERWhile the risk, is deemed low, cats should be monitored closely for infusion-related reactions when epirubicin is administered as hypersensitivity reactions can be serious and require urgent intervention. It may also be prudent to consider a slower rate of drug infusion. If a reaction occurs then drug administration should be discontinued and treatment with H1-antagonists, corticosteroids and/or adrenaline given, depending on severity. Infusion could be continued if the reaction was mild and the clinical signs controlled but this will be case-dependent. The current case suggests that further doses of epirubicin may be administered after hypersensitivity has been observed following H1 blockade. Further studies would however be required to corroborate this. Given the seemingly low incidence of hypersensitivity during epirubicin infusions in cats, it is not believed that routine premedication is necessary at this time.

show abstract

Toxicity associated with epirubicin treatments in a large case series of dogs

Cited by 15 publications

References 26 publications

Use of accelerometry to investigate physical activity in dogs receiving chemotherapy

Use of accelerometry to investigate physical activity in dogs receiving chemotherapy

Epirubicin in the treatment of canine histiocytic sarcoma: sequential, alternating and rescue chemotherapy

Hypersensitivity reaction during epirubicin infusion in a cat

Contact Info

Product

Resources

About